ArticleAdvances in therapy2018

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

André P Nicklas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.